NMRA Oct 2024 12.500 call
| Previous close | 1.5000 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 2.5000 |
| Strike | 12.50 |
| Expiry date | 2024-10-18 |
| Day's range | 1.5000 - 1.5000 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
GlobeNewswireNeumora Therapeutics Announces Initiation of Phase 1b Study of NMRA-511 for Treatment of Alzheimer’s Disease Agitation
NMRA-511 is a highly potent and selective, best-in-class, antagonist of the vasopressin 1a receptor, which is known to play a role in regulation of aggression, stress and anxiety response NMRA-511 was generally well-tolerated at all dose levels in Phase 1 single ascending dose / multiple ascending dose study, with no serious adverse events reported to date Alzheimer’s disease agitation is associated with increased morbidity and mortality and creates significant burden for patients and caregivers
Simply Wall St.This Neumora Therapeutics Insider Increased Their Holding In The Last Year
Insiders were net buyers of Neumora Therapeutics, Inc.'s ( NASDAQ:NMRA ) stock during the past year. That is, insiders...
- GlobeNewswire
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression
Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study Navacaprant is also currently in Phase 3 development for the treatment of MDD with data from KOASTAL-1 anticipated in the fourth quarter of 2024 WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pip
